Bunge Global
BG · NYSEFats & Oils · Fiscal year ends Dec 31
Bunge Global reported revenue of $16.9B in the fiscal year ended Dec 2025, up 9.0% from the year before. Net income was $816M. Operating cash flow of $844M less capital expenditure of $1.7B left free cash flow of −$879M. Net debt was $9B.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | $16.8B | $21.1B | $17.8B | $15.6B | $16.9B |
| Cost of revenue | $55.8B | $63.6B | $54.7B | $49.7B | $66.9B |
| Gross profit | $3.4B | $3.7B | $4.8B | $3.4B | $3.4B |
| Research & development | $33M | $33M | $35M | $30M | $28M |
| Selling, general & admin | $1.2B | $1.4B | $1.7B | $1.8B | $2.1B |
| Interest expense | $243M | $403M | $516M | $471M | $628M |
| Pre-tax income | $2.6B | $2.1B | $3.1B | $1.5B | $1.1B |
| Income tax | $398M | $388M | $714M | $336M | $288M |
| Net income | $2.1B | $1.6B | $2.2B | $1.1B | $816M |
| Diluted EPS | 13.64 | 10.51 | 14.87 | 7.99 | 4.91 |
| Diluted shares | 152M | 153M | 151M | 142M | 166M |
Balance sheet
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $902M | $1.1B | $2.6B | $3.3B | $1.1B |
| Receivables | – | $2.8B | $2.6B | $2.1B | $3.9B |
| Inventory | – | $8.4B | $7.1B | $6.5B | $13.2B |
| Current assets | – | $16.8B | $16.4B | $16B | $24.4B |
| Net PP&E | – | $3.6B | $4.5B | $5.3B | – |
| Goodwill | – | $470M | $489M | $453M | $3.1B |
| Total assets | $23.8B | $24.6B | $25.4B | $24.9B | $44.5B |
| Payables | – | $4.4B | $3.7B | $2.8B | $4.9B |
| Deferred revenue | – | $601M | $463M | $501M | $814M |
| Current liabilities | – | $9.6B | $7.7B | $7.4B | $15.1B |
| Short-term debt | – | $846M | $5M | $669M | $1.3B |
| Long-term debt | – | $3.3B | $4.1B | $4.7B | $8.8B |
| Shareholders' equity | $7.8B | $9.2B | $10.9B | $9.9B | $15.9B |
Cash flow
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −$2.9B | −$5.5B | $3.3B | $1.9B | $844M |
| Capital expenditure | $399M | $555M | $1.1B | $1.4B | $1.7B |
| Free cash flow | −$3.3B | −$6.1B | $2.2B | $524M | −$879M |
| Depreciation & amortisation | $424M | $408M | $451M | $468M | $703M |
| Stock-based compensation | $61M | $65M | $69M | $65M | $73M |
| Acquisitions | – | – | $0 | $0 | $4.2B |
| Share buybacks | $100M | $200M | $600M | $1.1B | $551M |
| Dividends paid | $289M | $349M | $383M | $378M | $459M |
| Dividend per share | 2.08 | 2.40 | 2.61 | 2.72 | 2.80 |
Key ratios
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 25.4% | −15.4% | −12.8% | 9.0% |
| EPS growth (YoY) | – | −22.9% | 41.5% | −46.3% | −38.5% |
| Gross margin | 20.0% | 17.5% | 27.2% | 21.8% | 20.1% |
| Net margin | 12.4% | 7.6% | 12.6% | 7.3% | 4.8% |
| Return on equityBlank when equity is negative | 26.6% | 17.5% | 20.7% | 11.5% | 5.1% |
| Free cash flow margin | −19.6% | −29.0% | 12.3% | 3.4% | −5.2% |
| Cash conversion (CFO ÷ net income) | −1.39x | −3.45x | 1.47x | 1.67x | 1.03x |
| Receivable days | – | 49 | 53 | 50 | 83 |
| Inventory days | – | 48 | 47 | 48 | 72 |
| Payable days | – | 25 | 24 | 20 | 27 |
| Debt ÷ equity | – | 0.45x | 0.38x | 0.54x | 0.64x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | – | $3B | $1.5B | $2.1B | $9B |
| Current ratio | – | 1.75x | 2.13x | 2.15x | 1.61x |
Recent filings
More in Fats & Oils
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.